使用在治疗乙肝表面抗原定量分析的基础上聚乙二醇干扰素

StephenW

Original Article

Hepatology International

October 2015, Volume 9, Issue 4, pp 543-557

First online: 11 July 2015
Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis

    Hong Peng, Fang Wei, Jun-Ying Liu, Huai-Dong Hu, Hong Ren, Peng Hu

Author Affiliations

        1. Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, LinjiangRoad#76, Yuzhong District, Chongqing, 400010, China
        2. Department of Infectious Diseases, The Guizhou Province People’s Hospital, Guiyang, Guizhou Province, China
        3. Department of Gastroenterology, The Central Hospital of Zhoukou, Zhoukou, Henan Province, China



Abstract
Purpose

The efficacy of on-treatment hepatitis B surface antigen (HBsAg) levels in guiding pegylated interferon (PEG-IFN) therapy for chronic hepatitis B (CHB) infections is still controversial. The aim of this study is to quantitatively evaluate the efficacy of on-treatment HBsAg levels as a response-guided therapy strategy to guide PEG-IFN-based therapies for CHB.
Methods

We searched PUBMED, EMBASE, and the Cochrane Library (1997–2013) for clinical research involving HBsAg quantification, and the response to PEG-IFN-based therapy. Pooled effect of HBsAg levels on guiding PEG-IFN-based therapies for CHB was evaluated using fixed-effects or random-effects model.
Results

From 13 studies (n = 1493 patients), patients with optimal on-treatment HBsAg levels were found to have a greater chance of attaining a response (RR 5.17, 95 % CI 3.75–7.11, p < 0.00001), and the pooled total response rate was 54 % (95 % CI 44–63 %). At week 12, patients without optimal on-treatment HBsAg levels had hardly achieved a response (the early non-response rate: 99 %, 95 % CI 98–100 %). At 24 weeks, the response rate increased to 79 % in HBeAg-negative patients.
Conclusion

This meta-analysis suggested that on-treatment HBsAg quantification is effective in guiding the therapy of PEG-IFN in CHB infections, especially in HBeAg-negative patients.
Keywords
HBV DNA Antiviral treatment Sero conversion Nucleot(s)ide analogs
Electronic supplementary material

The online version of this article (doi:10.​1007/​s12072-015-9644-y) contains supplementary material, which is available to authorized users.

StephenW

原创文章

肝病国际

2015年10月，第9卷，第4期，第543-557

首先在线：2015年7月11日
使用在治疗乙肝表面抗原定量分析的基础上聚乙二醇干扰素治疗慢性乙型肝炎治疗方案的应答指导治疗的Meta分析

    康鹏，方伟，刘俊英，怀董狐，弘仁，彭虎

作者机构

        传染病研究所病毒性肝炎1系，分子生物学传染病重点实验室，教育部，重庆医科大学附属第二医院，LinjiangRoad＃76，重庆市渝中区，重庆，400010，中国的
        传染病系，贵州省人民医院，贵阳市，贵州省，中国
        消化内科，周口市中心医院，河南周口，中国的3系



抽象的
用途

在治疗乙肝表面抗原（HBsAg的）在指导聚乙二醇干扰素（PEG-IFN）治疗慢性乙型肝炎（CHB）感染水平的疗效仍有争议。此研究的目的是定量地评价对治疗HBsAg水平的效力作为响应引导治疗策略来指导的PEG-IFN-α疗法为CHB。
方法

我们检索PubMed，文摘，和Cochrane图书馆（1997至2013年），涉及的HBs​​Ag定量临床研究，并应对PEG-IFN为基础的治疗。使用固定效应或随机效应模型HBsAg水平对指导PEG-IFN为基础的治疗慢性乙型肝炎合并效应进行了评价。
结果

从13研究（n = 1493例），患者最佳的治疗中发现HBsAg水平有实现的响应（RR 5.17，95％CI 3.75-7.11，P <0.00001）的机会较大，而合并总响应率为54％（95％CI：44-63％）。 12周时，患者无理想的治疗HBsAg水平已难以实现的响应（早期无应答率：99％，95％CI为98-100％）。在第24周时，响应率提高到79％，在HBeAg阴性患者。
结论

此荟萃分析表明，在治疗乙肝表面抗原定量分析是有效的指导PEG-IFN的慢性乙型肝炎感染的治疗，尤其是在HBeAg阴性的患者。
关键词
HBV-DNA抗病毒治疗的血清转换Nucleot（S）类似物
电子辅助材料

（DOI：10 1007 / s12072-015-9644-Y）本文的在线版本包含补充材料，这是提供给授权用户。